Invasive pulmonary aspergillosis in a hematooncological patient in the intensive care units. A review of the literature;Aspergilosis pulmonar invasiva en el paciente hematooncológico en las unidades de cuidados intensivos. Revisión de la literatura médica

Medicina Intensiva

Volumn 34, Issue 7, 2010, Pages 459-466

  Burghi, G ^a   Lemiale, V ^b   Bagnulo, H ^a   Bodega E ^a   Azoulay, E ^b  

^a HOSPITAL MACIEL   (Uruguay)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Galactomannan; Invasive aspergillosis; Voriconazole

Indexed keywords

1,3 BETA GLUCANASE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANCER PATIENT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIAGNOSTIC TEST; DRUG ANTAGONISM; DRUG POTENTIATION; DYSPNEA; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FEVER; FUNGUS CULTURE; HEMATOLOGIC MALIGNANCY; HUMAN; INTENSIVE CARE UNIT; LUNG ASPERGILLOSIS; LUNG SURGERY; MEDICAL LITERATURE; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PATIENT CARE; POLYMERASE CHAIN REACTION; PROGNOSIS; RESPIRATORY FAILURE; SYMPTOM; THORAX PAIN; THORAX RADIOGRAPHY;

HEMATOLOGIC NEOPLASMS; HUMANS; INTENSIVE CARE UNITS; PULMONARY ASPERGILLOSIS;

EID: 77956925972     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2009.11.010     Document Type: Article

References (72)

1. Sans Alonzo M.A., Jarque Ramos I., Salavert Lletí M., Pemán J. Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes. Clin Microbiol Infect 2006, 12:2-6.
2. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of multicenter Prospective Antifungal Therapy (PATH) Alliance Registry. Clin Infect Dis 2009, 48:265-273.
3. Dupont B. An epidemiological review of systemic fungal infections. J Mycol Med 2002, 12:163-173.
4. García Vidal C., Upton A., Kirby K., Marr K.A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to the time after transplantation. Clin Infect Dis 2008, 47:1041-1050.
5. Ewig S., Torres A., Riquelme R., El-Ebiary M., Rovira M., Carreras E., et al. Pulmonary complications in patients with haematological malignances treated at a respiratory ICU. Eur Respir J 1998, 12:116-122.
6. Rañó A., Agustí C., Jimenez P., Angrill J., Benito N., Danés C., et al. Pulmonary infiltrates in non-HIV immunocompromised patients: A diagnostic approach using non-invasive and bronchoscopic procedures. Thorax 2001, 56:379-387.
7. Danés C., González Martin J., Pumarola T., Rañó A., Benito N., Torres A., et al. Pulmonary infiltrates in immunosuppressed patients: Analysis of a diagnostic protocol. J Clin Microbiol 2002, 40:2134-2140.
8. Azoulay E., Thiéry G., Chevret S., Moreau D., Darmon M., Bergeron A., et al. The prognosis of acute respiratory failure in critically ill cancer patients. Medicine (Baltimore) 2004, 83:360-370.
9. Azoulay E., Mokart D., Rabbat A., Pene F., Kouatchet A., Bruneel F., et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: Prospective multicenter data. Crit Care Med 2008, 36:100-107.
10. Cornillet A., Camus C., Nimubona S., Gandemer V., Tattevin P., Belleguic C., et al. Comparison of epidemiological clinical and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6 year survey. Clin Infect Dis 2006, 43:577-584.
11. Cordonnier C., Ribaud P., Herbrecht R., Milpied N., Valteau-Couanet D., Morgan C., et al. Prognostic factors for death due to invasive aspergillosis after stem cell trasnplantation: A 1 year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006, 42:955-963.
12. Cornely O.A. Aspergillus to Zygomycetes: causes risk factors, prevention, and treatment of invasive fungal infections. Infection 2008, 36:296-313.
13. Pemán García J. Aspectos epidemiológicos de las micosis en el paciente crítico. Rev Esp Quimioter 2008, 21:7-8.
14. Muñoz P., Guinea J., Bouza E. Update on invasive aspergillosis: Clinical and diagnostic aspects. Clin Microbiol Infect 2006, 12:24-39.
15. Jantunen E., Piilonen A., Volin L., Parkkali T., Koukila-kähkölä P., Ruutu T., et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT. Bone Marrow Transplant 2000, 25:867-871.
16. Zmeili O.S., Soubani A.O. Pulmonary aspergillosis: A clinical update. Q J Med 2007, 100:317-334.
17. Meersseman W., Lagrou K., Maertens J., Van Wijngaerden Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007, 45:205-216.
18. Klont R.R., Meis J.F., Verwiej P.E. Critical assessment of issues in the diagnosis of invasive aspergillosis. Clin Microbiol Infect 2001, 7:32-37.
19. Shaukat A., Bakri F., Young P., Hahn T., Ball D., Baer M.R., et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics. Mycopathologia 2005, 159:181-188.
20. Caillot D., Casasnovas O., Bernard A., Couaillier J.F., Durand C., Cuisenier B., et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997, 15:139-147.
21. Greene R.E., Schlamm H.T., Oestmann J.W., Stark P., Durand C., Lortholary O., et al. Imaging findings in acute pulmonary aspergillosis: Clinical significance of the halo sign. Clin Infect Dis 2007, 44:373-379.
22. Caillot D., Couaillier J.F., Bernard A. Increasing volume and changing characteristic of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19:253-259.
23. Trof R.J., Beishuizen A., Debets-Ossenkopp Y.J., Girbes A.R., Groeneveld A.B. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patient. Crit care Med 2007, 33:1694-1703.
24. Pfeiffer C.D., Fine J.P., Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006, 42:1417-1427.
25. Maertens J.A., Klont R., Masson C., Theunissen K., Meersseman W., Lagrou K., et al. Optimization of the cutoff value for the aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007, 44:1329-1336.
26. Bergeron A, Belle A, Sulahian A, Lacroix C, Chevret S, Raffoux E, et al. Contribution of galactomannan antigen detection in bronchoalveolar lavage to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest. 2009; doi:101378/chest09-0701, Epub ahead of print.
27. Meersseman W., Lagrou K., Maertens J., Wilmer A., Hermans G., Vanderschueren S., et al. Galactomannan in bronchoalveolar lavage fluid. A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008, 177:27-34.
28. Husain S., Paterson D.L., Studer S.M. Aspergillus galactomannan antigen in the bronchoalveolar lavage for the diagnosis of invasive asprgillosis in lung transplant recipients. Transplantation 2007, 83:1330-1336.
29. Miceli M.H., Grazziutti M.L., Woods G., Zhao W., Kocoglu M.H., Barlogie B., et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: Clinical and research implications. Clin Infect Dis 2008, 46:1412-1422.
30. Fortún J., Martín-Dávila P., Álvarez M.E., Norman F., Sánchez-Sousa A., Gajate L., et al. False positive results of aspergillus galactomannan antigenemia in liver trasnplant recipients. Transplantation 2009, 87:256-260.
31. Weisser M., Rausch C., Droll A. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignances. Clin Infect Dis 2005, 41:1143-1149.
32. Rovira M., Jiménez M., Puig de la Bellacasa J., Mensa J., Rafel M., Ortega M., et al. Detection of aspergillus galactomannan by enzime immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: A prospective study. Transplantation 2004, 77:1260-1264.
33. Hidalgo A., Parody R., Martino R., Sánchez F., Franquet T., Giménez A., et al. Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis. Eur J Radiol 2009, 71:55-60.
34. Quindòs G. New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi. Clin Microbiol Infect 2006, 12:40-52.
35. White P.L., Linton C.J., Perry M.D., Johnson E.M., Barnes R.A. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006, 42:479-486.
36. Kawazu M., Kanda Y., Nannya Y., Aoki K., Kurokawa M., Chiba S., et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-3)B-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004, 42:2733-2741.
37. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., Vázquez J., Pappas P.G., Saeki F., et al. Multicenter clinical evaluation of the (1-3)B-D-Glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659.
38. Mennink M., Verweij P.E. Non-culture-based diagnosittcs for opportunistic fungi. Infect Dis Clin N Am 2006, 711-727.
39. Segal B.H., Walsh T.J. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006, 173:707-717.
40. Florent M., Katsahian S., Vekhoff A., Levy V., Río B., Marie J.P., et al. Prospective evaluation of polymerase chain reaction-elisa targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006, 193:741-747.
41. Khot P.D., Ko D.L., Hackman R.C., Fredricks D.N. Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infectious Disease 2008, 8:73-85.
42. Kami M., Ogawa S., Kanda Y., Tanaka Y., Machida U., Matsumura T., et al. Early diagnosis of central nervous system aspergillosis usisng polymerase chain reaction, latex aglutination test, and enzyme-linked immunosorbent assay. Br J Haematol 1999, 106:536-537.
43. Bouza E., Guinea J., Peláez T., Pérez-Molina J., Alcalá L., Muñoz P. Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. J Clin Microbiol 2005, 43:2075-2079.
44. Simoneau E., Kelly M., Labbe A.C., Roy J., Laverdière M. What is the clinical significance of positive blood cultures with Aspergillus sp. in hematopoietic stem cell transplant recipients? A 23 years experience. Bone Marrow Transplantation 2005, 35:303-306.
45. Perfect J.R., Cox G.M., Lee J.Y., Kauffman C.A., de Repentigny L., Chapman S.W., et al. The impact of culture isolation of aspergillus species: A hospital-based survey of aspergillosis. Clin Infect Dis 2001, 33:1824-1833.
46. Soubani A.O., Khanchandani G., Ahmed H.P. Clinical significance of lower respiratory tract Aspergillus culture in elderly hospitalized patients. Eur J Clin Microbiol Infect dis 2004, 23:491-494.
47. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
48. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999, 340:764-771.
49. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007, 44:1289-1297.
50. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Tratamiento de la aspergilosis:guías para la pŕctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos(IDSA). Clin Infect Dis 2008, 46:T1-T36.
51. Herbretcht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmenn J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
52. Guinea J., Recio S., Peláez T., Torres-Narbona M., Bouza E. Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. Antimicrob Agents Chemother 2008, 52:3444-3446.
53. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
54. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201-211.
55. Smith J.A. What is the role of therapeutic drug monitoring in antifungal therapy?. Curr Infect Dis Rep 2009, 11:439-446.
56. Lanternier F., Lortholary O. Liposomal amphotericin B: What is its role in 2008?. Clin Microbiol Infect 2008, 14:71-83.
57. Flückiger U., Marchetti O., Bille J., Eggimann P., Zimmerli S., Imhof A., et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006, 136:447-463.
58. Caillot D., Thiébaut A., Herbrecht R., de Botton S., Pigneux A., Bernard F., et al. Liposomal amphotericin B in combination with capsofungin for invasive aspergillosis in patients with hematologic malignancies. Cancer 2007, 110:2740-2746.
59. Maertens J., Glasmacher A., Herbrecht R., Thiebaut A., Cordonnier C., Segal B.H., et al. Multicenter, noncomparative study of capsofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006, 107:2888-2897.
60. Vázquez J.A. Combination antifungal therapy for mold infections: Much about nothing?. Clin Infect Dis 2008, 46:1889-1901.
61. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.j., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
62. Siwek G.T., Pfaller M.A., Polgreen P.M., Cobb S., Hoth P., Magalheas-Silverman M., et al. Incidence of invasive aspergillosis among allogeneic hmatopoietic stem cell trasnplant patients receiving voriconazole prophylaxis. Diag Microbiol Inf Dis 2006, 55:209-212.
63. Rijnders B.J., Cornelissen J.J., Slobbe L., Becker M.J., Doorduijn J.K., Hop W.C., et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized placebo-controlled trial. Clin Infect Dis 2008, 46:1401-1408.
64. Cornely O.A., Böhme A., Buchheidt D., Einsele H., Heinz W.J., Karthaus M., et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology an Oncology. Haematologica 2009, 94:113-122.
65. Steinbach W.J., Stevens D.A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003, 37:S157-S187.
66. Vandewoude K.H., Blot S.I., Benoit D., Colardyn F., Vogelaers D. Invasive aspergillosis in critically ill patients: Atributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004, 56:269-276.
67. Janssen J.J., Strack van Schijndel R.J., van der Poest Clement E.H., Ossenkoppele G.J., Thijs L.G., Huijgens P.C. Outcome of ICU treatment in invasive aspergillosis. Intensive Care med 1996, 22:1315-1322.
68. Nivoix Y., Velten M., Letscher-Bru V., Moghaddam A., Natarajan-Amé S., Fohrer C., et al. Factors associated with overall and atributable mortality in invasive aspergillosis. Clin Infect Dis 2008, 47:1176-1184.
69. Upton A., Kirby K.A., Carpernter P., Boeckh M., Marr K.A. Invasive aspergillosis following hematopoietic cell trasnplantion: Outcomes and pronostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
70. Hernández Sierra B., Prieto Palomino M.A., Curiel Balestra E., Muñoz Bono J., Quesada García G., Arias Verdú M.D. Perfil clínico-epidemiológico y taxonómico de la candidiasis sistémica en una unidad de cuidados intensivos. Med Intensiva 2009, 33:144-147.
71. Barnes P.D., Marr K.A. Risks, diagnosis and outcomes of invasive fungal infections in haemopoietic stem cell transplant recipients. British J Haematol 2007, 139:519-531.
72. Offner F., Cordonnier C., Ljungman P., Prentice H.G., Engelhard D., De Bacquer D., et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998, 26:1098-1103.